Ownership and insider activity for Pasithea Therapeutics Corp. (KTTA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.
Price
| Price | $0.49 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-17 | Coastlands Capital LP | P-Purchase | 100,000 | $53K |
| 2026-05-01 | Marques Tiago | A-Award | 1,756,069 | $1.5M |
| 2026-05-01 | STEINMAN LAWRENCE | A-Award | 152,783 | $128K |
| 2026-05-01 | Dumesnil Simon | A-Award | 152,783 | $128K |
| 2026-05-01 | Schneiderman Daniel H | A-Award | 1,129,323 | $950K |
| 2026-05-01 | Krishnan Kartik | A-Award | 1,129,323 | $950K |
| 2026-05-01 | Leahy Emer | A-Award | 152,783 | $128K |
| 2026-05-01 | Novak Alfred J | A-Award | 152,783 | $128K |
| 2026-05-01 | Krishnan Kartik | |||
| 2026-04-09 | Coastlands Capital LP |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $243650 | $53.0M | $33.1M | $16.3M | $6.9M | $55.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $40500 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $247958 | $53.3M | $34.1M | $16.7M | $7.4M | $56.5M |
| Property, Plant & Equipment | 0 | $20124 | $625625 | $220479 | $122343 | 0 |
| Goodwill | 0 | 0 | $1.3M | $1.3M | $1.3M | 0 |
| Intangible Assets | 0 | 0 | $8.6M | $7.9M | $7.3M | $3.8M |
| Total Assets | $247958 | $53.3M | $45.2M | $26.1M | $16.1M | $60.2M |
| Accounts Payable | $6603 | 0 | $1.5M | 0 | 0 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6603 | $447280 | $1.9M | $2.6M | $1.1M | $5.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6603 | $1.9M | $2.7M | $2.7M | $1.3M | $5.0M |
| Retained Earnings | -$40984 | -$2.2M | -$19.4M | -$35.3M | -$49.6M | -$70.0M |
| Total Equity | $241355 | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M |
| Total Debt | 0 | 0 | $504383 | $81680 | 0 | 0 |
| Net Debt | -$243650 | -$53.0M | -$32.6M | -$16.2M | -$6.9M | -$55.2M |
| Working Capital | $241355 | $52.9M | $32.2M | $14.1M | $6.2M | $51.5M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 26.25 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -0.66 |
Profitability
| Return on Equity | -49.49% |
| Return on Invested Capital | -48.04% |
| Return on Assets | -41.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CYCN · IBO · KALA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of KTTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks